December 20, 2022 AlzeCure gets abstract accepted on new potential disease-modifying effects of ACD856 against Alzheimer’s
December 15, 2022 AlzeCure gets late-breaking abstract on new data with its Alzheimer project Alzstatin accepted at AD/PD 2023
December 13, 2022 AlzeCure Pharma AB’s Chief Scientific Officer has participated in an interview with Erik Penser Bank
December 6, 2022 The subscription period in AlzeCure Pharma AB’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank
December 1, 2022 New data on Alzstatin for preventive treatment against Alzheimer’s presented at Alzheimer’s conference CTAD
November 30, 2022 New data strengthening the continued clinical development of NeuroRestore ACD856 presented at Alzheimer’s conference
October 24, 2022 AlzeCure gets abstract accepted on positive clinical EEG results with Alzheimer’s project NeuroRestore ACD856
October 20, 2022 AlzeCure presents new data with its preventive treatment Alzstatin at the Alzheimer conference CTAD
October 18, 2022 AlzeCure gets new abstract accepted on ACD856’s indicative disease-modifying effects against Alzheimer’s
October 11, 2022 New data from AlzeCure demonstrate potential disease-modifying effects of NeuroRestore ACD856
October 6, 2022 AlzeCure presents its project portfolio in Alzheimer’s and pain at Redeye’s theme day on October 12
September 22, 2022 AlzeCure presents new data on the anti-inflammatory effects of its TrkA-NAM pain project at IASP 2022
September 16, 2022 AlzeCure’s Alzheimer’s project NeuroRestore ACD856 shows positive effect on brain activity in clinical trial
August 30, 2022 AlzeCure gets abstract accepted on potential neuroprotective effects of NeuroRestore ACD856
August 16, 2022 New review article on AlzeCure’s NeuroRestore as a novel Alzheimer’s therapy published in Drug Discovery Today
August 2, 2022 AlzeCure presents new clinical data with NeuroRestore ACD856 at the Alzheimer’s conference AAIC
July 5, 2022 AlzeCure gets abstract on new clinical study data with NeuroRestore accepted at the Alzheimer’s conference AAIC
June 21, 2022 First patient included in AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440
June 15, 2022 Study plan of AlzeCure’s Phase II clinical study in neuropathic pain with non-opioid ACD440 now available
May 25, 2022 AlzeCure gets approval to start Phase II clinical trial with non-opioid pain project ACD440
May 10, 2022 AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference
March 17, 2022 AlzeCure presents new data at AD/PD meeting on NeuroRestore’s positive effect on mitochondrial function
March 8, 2022 AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease
February 8, 2022 AlzeCure is moving towards Phase IIa clinical trial with ACD440 based on guiding response from the FDA
January 27, 2022 Novel data in Alzstatin Alzheimer’s project presented at the 11th Pharmaceutical Profiling meeting
January 18, 2022 AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference
January 11, 2022 AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function
